{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:28:22Z","timestamp":1776410902478,"version":"3.51.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Esophageal cancer incidence is rising globally, with at least 500,000 new cases diagnosed annually. Management options for non-metastatic disease include primary resection, neoadjuvant or perioperative therapies, or definitive non-surgical treatment, with the choice being guided by tumor staging, histology, patient fitness, and available resources. However, even with the use of advanced diagnostic modalities, preoperative clinical staging is challenging with respect to accuracy of both tumor and nodal assessment. Early-stage esophageal cancer may be managed with local therapies, such as endoscopic mucosal resection or submucosal dissection, while for more advanced tumors managed with curative intent neoadjuvant oncologic therapy is commonly recommended. However, between these two groups lies an infrequent but important subgroup of patients, clinically staged cT2N0M0 esophageal cancer. Guidelines such as the NIH\u2019s National Cancer Institute recommends either surgery alone or neoadjuvant therapy followed by surgery for AJCC Stage I cancers, and add the option of definitive chemoradiation for Stage II disease. With cT2N0 disease straddling both AJCC classifications, management guidance is lacking. This guideline will provide an evidence-based recommendation from the International Society For Disease Of The Esophagus on the management of cT2N0 esophageal cancer, of all types. The recommendations are intended to support surgeons, oncologists, and patients in decisions about the best practice preoperative oncologic management of cT2N0M0 esophageal cancer.<\/jats:p>\n                  <jats:p>A Working Group within the International Society for Diseases of the Esophagus (ISDE) Guidelines Committee performed a systematic review of the literature. Results of the systematic review were presented to a panel of experts and these results informed the panel discussion about the guideline. This panel used Grading of Recommendations Assessment, Development, and Evaluation approach to deliberate and formulate recommendations.<\/jats:p>\n                  <jats:p>The panel agreed on a conditional recommendation for the use of neoadjuvant therapy followed by surgery over primary surgical resection (PSR) for adult patients with cT2N0M0 esophageal cancer.<\/jats:p>\n                  <jats:p>Preoperative clinical staging of esophageal cancer is uncertain, with deficiencies in all diagnostic modalities. However, when all modern staging techniques are utilized, the ISDE recommends neoadjuvant therapy followed by surgical resection as the favored treatment of cT2N0 esophageal cancer. Certain patient groups may still be offered PSR, particularly those unable to tolerate neoadjuvant therapies, or those patients with very low risk of lymph node metastasis as suggested by histological features, small tumor size, and other features.<\/jats:p>","DOI":"10.1093\/dote\/doag019","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:19:22Z","timestamp":1771244362000},"source":"Crossref","is-referenced-by-count":0,"title":["ISDE guidelines on the management of cT2N0 esophageal cancer"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7708-7859","authenticated-orcid":false,"given":"Geoffrey P","family":"Kohn","sequence":"first","affiliation":[{"name":"Department of Surgery , , Melbourne, Vic ,","place":["Australia"]},{"name":"Monash University , , Melbourne, Vic ,","place":["Australia"]},{"name":"Department of Surgery, Cabrini Health , Melbourne, Vic ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Litle","sequence":"additional","affiliation":[{"name":"Sutter Health , San Francisco, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif","family":"Eliya","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cabrini Health , Melbourne, Vic ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Surgery , , Melbourne, Vic ,","place":["Australia"]},{"name":"Eastern Health , , Melbourne, Vic ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Asghari-Jafarabadi","sequence":"additional","affiliation":[{"name":"Cabrini Research, Cabrini Health, Malvern , Vic 3144 ,","place":["Australia"]},{"name":"School of Public Health and Preventive Medicine, Monash University , Melbourne, Vic ,","place":["Australia"]},{"name":"Department of Psychiatry, School of Clinical Sciences, Monash University , Clayton, Vic ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Contreras","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Utah , Salt Lake City, UT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Surgery, Guy\u2019s and St Thomas\u2019 National Health Service Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudy","family":"Lackner","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Thoracic Surgery, University of Nebraska , Omaha, NE ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley S","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Boston Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Mala","sequence":"additional","affiliation":[{"name":"Section of Upper Gastrointestinal Surgery, Oslo University Hospital\/University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Markman","sequence":"additional","affiliation":[{"name":"Department of Surgery , , Melbourne, Vic ,","place":["Australia"]},{"name":"Monash University , , Melbourne, Vic ,","place":["Australia"]},{"name":"Alfred Health , Melbourne, Vic ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarbajit","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute , Baptist Health South Florida, Miami, FL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Nevala-Plagemann","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Smyth","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oxford University Hospitals National Health Service Foundation Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Sultan","sequence":"additional","affiliation":[{"name":"Salford Royal Hospital, Northern Care Alliance National Health Service Foundation Trust , Salford ,","place":["UK"]},{"name":"Division of Cancer Sciences, School of Medical Sciences, University of Manchester"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Worrell","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Thoracic Surgery, University of Arizona , Tucson, AZ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-781X","authenticated-orcid":false,"given":"Shun","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-3697","authenticated-orcid":false,"given":"Bas P L","family":"Wijnhoven","sequence":"additional","affiliation":[{"name":"Department of Surgery, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6630-3547","authenticated-orcid":false,"given":"Ewen A","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Department of Upper Gastrointestinal Surgery, University Hospitals Birmingham National Health Service Foundation Trust , Birmingham ,","place":["UK"]},{"name":"Institute of Immunotherapy and Immunology, University of Birmingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026041702363815200_ref1","volume-title":"European Cancer Information System","author":"Commission E","year":"2025"},{"issue":"5","key":"2026041702363815200_ref2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ejso.2018.02.005","article-title":"Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: a population-based cohort study","volume":"44","author":"Goense","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2026041702363815200_ref3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejca.2015.11.024","article-title":"Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study","volume":"56","author":"Markar","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"2026041702363815200_ref4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2017.73.7718","article-title":"Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial","volume":"36","author":"Noordman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026041702363815200_ref5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","article-title":"ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)","volume":"16","author":"Hoeppner","year":"2016","journal-title":"BMC Cancer"},{"key":"2026041702363815200_ref6","doi-asserted-by":"publisher","first-page":"A5","DOI":"10.1016\/j.jclinepi.2021.04.008","article-title":"Prisma 2020","volume":"134","author":"Tugwell","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"2026041702363815200_ref7","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00464-021-08469-z","article-title":"Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) guidelines development: standard operating procedure","volume":"35","author":"Rogers","year":"2021","journal-title":"Surg Endosc"},{"key":"2026041702363815200_ref8","volume-title":"Ann Intern Med"},{"issue":"4","key":"2026041702363815200_ref9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/dote.12334","article-title":"Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy","volume":"29","author":"Dolan","year":"2016","journal-title":"Dis Esophagus"},{"issue":"3","key":"2026041702363815200_ref10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1442-2050.2011.01243.x","article-title":"Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma","volume":"25","author":"Chen","year":"2012","journal-title":"Dis Esophagus"},{"issue":"13","key":"2026041702363815200_ref11","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.1245\/s10434-021-10194-9","article-title":"Optimal treatment of cT2N0 esophageal carcinoma: is upfront surgery really the way?","volume":"28","author":"Capovilla","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2026041702363815200_ref12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","article-title":"A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III esophageal squamous cell carcinoma (JCOG0909 study)","volume":"114","author":"Takeuchi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2026041702363815200_ref13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jtcvs.2020.10.138","article-title":"Defining low-risk lesions in early-stage esophageal adenocarcinoma","volume":"162","author":"Sihag","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"13","key":"2026041702363815200_ref14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"2026041702363815200_ref15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/2\/doag019\/67244594\/doag019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/2\/doag019\/67244594\/doag019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:36:44Z","timestamp":1776407804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doag019\/8507416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doag019","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,2]]},"article-number":"doag019"}}